Separate names with a comma.
Turn On, Tune In, Buy Out: Who Follows AbbVie Into Psychedelic M&A? A recent Bloomberg article reported that AbbVie plans to acquire a...
The Psychedelic Sector Today: Momentum, Milestones, and What Lies Ahead...
In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals...
PSIL ETF upped ATAI holdings from 11% to 13.04% in the last 2 days.
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025 NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD)...
Incredible [IMG]
AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal...
Cathie Woods bought two times in the last week: [IMG]
Atai Life Sciences CEO provides updates and outlines next steps for BPL-003 and other program [MEDIA]
GH Research (GH001, inhalable 5‑MeO‑DMT): Reported strong Phase 2b data in February 2025, showing a placebo‑adjusted MADRS reduction of ~15.5...
#AlphaNooner - Inside $ATAI with Christian Angermayer [MEDIA]
Mind Medicine: Heading In The Right Direction https://seekingalpha.com/article/4803842-mind-medicine-heading-in-the-right-direction
ATAI Chairman Predicts his Company will Capture most of a Market Generating over 40b in Revenue a Year....
[IMG] 1. Expanding, differentiated product suite Sekur offers fully Swiss-hosted privacy tech—including encrypted email (SekurMail) with...
[IMG]
ATAI will squeeze soon
PBS - RFK Jr. suggests psychedelic therapy for depression and trauma has Trump administration’s support...
